强生公司将收购 Firefly Bio, Inc.，利用新型 Degrader 抗体偶联物平台扩大肿瘤产品线 - Johnson & Johnson

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform - Johnson & Johnson

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform Johnson & Johnson Johnson & Johnson to Buy Firefly Bio for $1 Billion WSJ J&J makes $1B bet on emerging DAC space by netting Firefly Bio Fierce Biotech J&J spends $1 billion to enter KRAS race for cancer treatments statnews.com J&J to buy cancer drug technology developer Firefly Bio for $1 billion Reuters

这条新闻具备可验证事件线索，可继续观察是否形成 Yes/No 预测问题。

同主题新闻会帮助 Google 识别事件簇，也让用户继续进入可交易话题。